Ovarian stimulation with HMG: Results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin

Human Reproduction

Volumn 15, Issue 3, 2000, Pages 526-531

  Albano, Carola ^b   Felberbaum, R E ^c   Smitz, J ^c   Riethmuller Winzen H ^a   Engel, J ^a   Diedrich, K ^c   Devroey, Paul ^b   Van Steirteghem, André ^b   Brinsden, Peter ^c   Akagbosu, F ^c   Lenton, Elizabeth ^d   Sundar, Eswar ^d   Sugantha, S E ^d   Fawzy, Medhat ^d   Yates, R W S ^e   Fleming, R ^e   Louis, E ^e   Baird, David ^f   Lawson, S ^f   West, C ^f   Kinniburgh, D ^f   Evers, Johannes ^g   Land, J A ^g   Maas, J W M ^g   Courtar, D ^g   Kahn, Jarl ^h   Christensen, F ^h   more..

^a ASTA MEDICA AG   (Germany)

^b CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

^c Bourn Hall Clinic ^*

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e GLASGOW ROYAL INFIRMARY   (United Kingdom)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h Ciconia Hospital   (Denmark)

Author keywords

Cetrorelix; Human menopausal gonadotrophins; LHRH agonist, buserelin; LHRH antagonist

Indexed keywords

BUSERELIN; BUSERELIN ACETATE; CETRORELIX; CHORIONIC GONADOTROPIN; ESTRADIOL; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; PROGESTERONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; GROWTH STIMULATION; HORMONE DEPENDENCE; HUMAN; INFERTILITY; INTRACYTOPLASMIC SPERM INJECTION; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY FOLLICLE; OVARY FOLLICLE DEVELOPMENT; PHASE 3 CLINICAL TRIAL; PROGESTERONE BLOOD LEVEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

FALLOPIA;

EID: 0034053260     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/15.3.526     Document Type: Article

References (22)

1. Albano, C., Smitz, J., Camus, M. et al. (1996) Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (cetrorelix). Hum. Reprod., 11, 2114-2118.
2. Albano, C., Smitz, J., Camus, M. et al. (1997) Comparison of different doses of gonadotropin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation. Fertil. Steril., 67, 917-922.
3. Ben-Rafael, Z., Bider, D., Menashe, Y. et al. (1990) Follicular and luteal cysts after treatment with gonadotropin-releasing hormone analog for in vitro fertilization. Fertil Steril., 53, 1091-1094.
4. Diedrich, K., Diedrich, C., Santos, E. et al. (1994) Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist cetrorelix during ovarian stimulation. Hum. Reprod., 9, 788-791.
5. Feldberg, D., Ashkenazi, J., Dicker, D. et al. (1989) Ovarian cyst formation: a complication of gonadotropin-releasing hormone agonist therapy. Fertil. Steril., 51, 42-45.
6. Hall, J. (1993) Gonadotropin-releasing hormone antagonists: effects on the ovarian follicle and corpus luteum. Clin. Obstet. Gynecol., 36, 744-752.
7. Hartung, J. (ed.) (1985) Statistik, Oldenbourg Verlag, München, p. 203.
8. Howles, C.M., Macnamee, M.C. and Edwards, R.G. (1987) Follicular development and early luteal function of conception and non-conception cycles after human in-vitro fertilization: endocrine correlates. Hum. Reprod., 2, 17-21.
9. Loumaye, E. (1990) The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer. Hum. Reprod., 5, 357-376.
10. MacLachlan, V., Besanko, M., O'Shea, F. et al. (1989) A controlled study of luteinizing hormone-releasing hormone agonist (buserelin) for the induction of folliculogenesis before in vitro fertilization. N. Engl. J. Med., 320, 1233-1237.
11. Minaretzis, D., Alper, M.M., Selwyn, P. et al. (1995) Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells. Am. J. Obstet. Gynecol., 172, 1518-1525.
12. Olivennes, F., Fanchin, R., Bouchard, P. et al. (1994) The single or dual administration of the gonadotropin-releasing hormone antagonist cetrorelix in an in vitro fertilization embryo transfer program. Fertil. Steril., 62, 468-476.
13. Olivennes, F., Fanchin, R., Bouchard, P. et al. (1995) Scheduled administration of gonadotropin-releasing hormone antagonist (cetrorelix) on day 8 of in-vitro fertilization cycles: a pilot study. Hum. Reprod., 10, 1382-1386.
14. Olivennes, F., Alvarez, S., Bouchard, P. et al. (1998) The use of a GnRH antagonist (cetrorelix) in a single dose protocol in IVF-embryo transfer of 3 versus 2 mg. Hum. Reprod., 13, 2411-2414.
15. Porter, R.N., Smith, W. and Craft, I.L. (1984) Induction of ovulation for in-vitro fertilization using buserelin and gonadotropins. Lancet, ii, 1284-1285.
16. Rongières-Bertrand, C., Olivennes, F., Righini, C. et al. (1999) Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (cetrorelix): a pilot study with minimal stimulation. Hum. Reprod., 14, 683-688.
17. Shaw, R.W., Ndukwe, G., Imoedemhe, D.A. et al. (1985) Twin pregnancy after pituitary desensitization with LHRH agonist and pure FSH. Lancet, ii, 506-507.
18. Smitz, J., Van den Abbeel, E., Bollen, N. et al. (1992) The effect of gonadotrophin-releasing hormone (GnRH) agonist in the follicular phase on in-vitro fertilization outcome in normo-ovulatory women. Hum. Reprod., 7, 1098-1102.
19. Stanger, J.D. and Yovich, J.L. (1985) Reduced in-vitro fertilization of human oocytes from patients with raised basal luteinizing hormones levels during the follicular phase. Br. J. Obstet. Gynaecol., 92, 385-393.
20. The ganirelix dose-finding group (1998) A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum. Reprod., 13, 3023-3031.
21. Van Steirteghem, A.C., Van der Elst, J., Van den Abbeel, E. et al. (1994) Cryopreservation of supernumerary multicellular human embryos obtained after intracytoplasmic sperm injection. Fertil. Steril., 62, 775-780.
22. Wildt, L., Diedrich, K., Van der Ven, X. et al. (1986) Ovarian hyperstimulation for in vitro fertilization controlled by GnRH agonist administered in combination with human menopausal gonadotropins. Hum. Reprod., 1, 15-19.